Anti-IL-17A (Taltz) (Ixekizumab biosimilar) mAb
For estimated delivery dates, please contact us at firstname.lastname@example.org
|Amount :||100 µg|
|Purification :||Purified from cell culture supernatant by affinity chromatography|
|Storage condition :||Store at -20°C to -80°C (Avoid repeated freezing and thawing).|
Ixekizumab/ Anti-IL-17A (Taltz) is a humanized IgG4 biosimilar monoclonal antibody expressed by mammalian cell lines that block the biological activity of IL-17A. IL-17A is a pro-inflammatory cytokine that triggers immune cells like neutrophils, lymphocytes, macrophages, monocytes, natural killer (NK) cells, and B cells that play essential roles in innate and adaptive immune responses. IL-17A binds IL17RA-IL17RC heterodimeric receptor complex to activate TRAF6 and NF-kappaB pathway, leading to pro inflammatory cytokines and chemokines gene expression. The Ixekizumab biosimilar developed by Abeomics is a high-quality research grade biosimilar and is not to be used for therapeutic or diagnostic procedures for humans and animals.
ELISA 1:5000-10000, FACS 1:100
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
There are currently no product reviews